Clinical trials: Pancreatic Cancer Borderline
Borderline and Locally Advanced Pancreatic Cancer
A Prospective Study of Concurrent Hyperthermia, Chemotherapy and Radiotherapy in Borderline and Locally Advanced Pancreatic Cancer (PANHEAT)
The project proposes a prospective multicenter study to evaluate the incorporation of deep regional hyperthermia into the standard of care neoadjuvant chemotherapy (mFOLFIRINOX/NABPACLITAXEL) followed by radiotherapy in…
- Trial name
- PANHEAT (NCT07839676)
- Testing
- Hyperthermia plus neoadjuvant chemotherapy/radiotherapy Arm Description: Hyperthermia plus neoadjuvant chemotherapy (mFOLFIRINOX/nab Paclitaxel) followed by a) surgically resectable: Hyp
- Where
- 2 sites in Spain
- Volunteers
- 60 people
- Sponsor
- Fernando Pessoa Canarias University
Pancreatic Cancer, Pancreatic Carcinoma Non-resectable
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Unfortunately, despite the best clinical efforts and breakthroughs in biotechnology, most patients diagnosed with pancreatic cancer continue to die from the rapid progression of their disease.
- Conditions
- Pancreatic Cancer, Pancreatic Carcinoma Non-resectable, Locally Advanced Malignant Neoplasm
- Trial name
- PILLAR (NCT01836432)
- Testing
- FOLFIRINOX, Algenpantucel-L Immunotherapy, 5-FU Chemoradiation
- Where
- 32 sites in United States
- Volunteers
- 302 people
- Sponsor
- NewLink Genetics Corporation
Ductal Adenocarcinoma of the Pancreas
Trial to Investigate Intensified Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer
The aim ot the study is to investigate the efficacy and safety of two new intensified chemotherapy regimens (gemcitabine (Gem)/nab- paclitaxel (PAC), FOLFIRINOX) as neoadjuvant chemotherapy protocol in locally advanced…
- Trial name
- NEOLAP (NCT02125136)
- Testing
- Gem/nab-Pac, FOLFIFINOX
- Where
- Germany
- Volunteers
- 168 people
- Sponsor
- AIO-Studien-gGmbH
Cancer of Pancreas, Pancreas Adenocarcinoma
Carbon Ions Radiation Therapy for Resectable or Borderline Resectable Pancreas Adenocarcinoma
Relapses free survival will be evaluated as efficacy of carbon ions radiation therapy released before surgery.
- Conditions
- Cancer of Pancreas, Pancreas Adenocarcinoma, Resectable Pancreatic Cancer
- Trial name
- PIOPPO (NCT03822936)
- Testing
- Preoperative chemotherapy, Preoperative radiotherapy
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- CNAO National Center of Oncological Hadrontherapy
Pancreatic Cancer
A Phase II Study to Assess the Efficacy and Safety of Preoperative Chemo With Radiation Therapy for Patients With Borderline Unresectable Adenocarcinoma of the Pancreas
The purpose of this phase II clinical trial study is to assess the resection rate among subjects who have been initially diagnosed with unresectable or borderline resectable pancreatic adenocarcinoma.
- Trial name
- NCT01240304
- Testing
- Gemcitabine, Radiation therapy, pancreaticoduodenectomy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Arkansas
Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma
SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial
This phase II trial tests the impact of using SMAD4-mutant status to personalize chemotherapy in treating patients with pancreatic ductal adenocarcinoma (PDAC) that can be removed by surgery (resectable) or that may be between…
- Trial name
- NCT07748611
- Testing
- Biospecimen Collection, Computed Tomography, Electronic Health Record Review
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- Northwestern University
Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma
Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Pancreatic Cancer
This phase I trial studies the side effects of losartan and hypofractionated radiation therapy after chemotherapy in treating patients with pancreatic cancer that may or may not be removed by surgery (borderline resectable) or…
- Conditions
- Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma, Locally Advanced Unresectable Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8
- Trial name
- SHAPER (NCT04106856)
- Testing
- Hypofractionated Radiation Therapy, Losartan, Losartan Potassium
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Utah
Borderline Resectable Pancreatic Cancer
Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer
The aim of this study is to clarify the efficacy and safety of neoadjuvant FOLFIRINOX and nab-paclitaxel + gemcitabine for borderline resectable pancreatic cancer.
- Trial name
- NCT02717091
- Testing
- FOLFIRINOX, gemcitabine + nab-paclitaxel
- Volunteers
- 50 people
- Sponsor
- Nagoya University
Pancreatic Cancer
Neoadjuvant S-1 and Concurrent Radiotherapy for Borderline Resectable Pancreatic Cancer
Multicenter Prospective Phase II Study for Neoadjuvant S-1 and Concurrent Radiotherapy for Borderline Resectable Pancreatic Cancer RATIONALE: Borderline resectable pancreatic cancer is frequently related to a positive surgical…
- Trial name
- NCT02459652
- Testing
- S-1, Radiation Therapy
- Where
- 22 sites in Japan
- Volunteers
- 57 people
- Sponsor
- Japan Adjuvant Study Group of Pancreatic Cancer
Pancreatic Adenocarcinoma
Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")
In this clinical trial, if the doctor knows or suspects that a growth in the pancreas is cancer (adenocarcinoma), then a sample of the growth is tested (the test is called molecular profiling).
- Trial name
- NCT01726582
- Testing
- Milestone 1: Targeted chemotherapy prior to surgery, Milestone 2: Chemoradiotherapy (cXRT), Milestone 3: Targeted chemotherapy prior to surgery
- Where
- 2 sites in United States
- Volunteers
- 229 people
- Sponsor
- Medical College of Wisconsin
Pancreatic Cancer Non-resectable, Chemotherapy Effect
Concurrent FOLFIRINOX Plus High Intensity Focused Ultrasound for Pancreatic Cancer
In patients diagnosed with locally advanced pancreatic cancer (LAPC)/borderline resectable pancreatic cancer (BRPC) and planned chemotherapy using FOLFIRINOX, high intensity focused ultrasound (HIFU)/FOLFIRINOX combined treatment…
- Conditions
- Pancreatic Cancer Non-resectable, Chemotherapy Effect, Ultrasound Therapy
- Trial name
- NCT05262452
- Testing
- ALPIUS 900, an ultrasound-guided high intensity focused ultrasound system, FOLFIRINOX regimen
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Seoul National University Hospital
Locally Advanced Pancreatic Cancer, Borderline Pancreatic Inoperable Cancer
Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer
This study will implement a new treatment regimen for patients with advanced and inoperable pancreatic cancer using chemotherapy combinations of Folfirinox or gemcitabine-nab paclitaxel (abraxane) followed by a short course of…
- Conditions
- Locally Advanced Pancreatic Cancer, Borderline Pancreatic Inoperable Cancer, Pancreatic Cancer
- Trial name
- NCT03600623
- Testing
- Folfirinox, Gemcitabine nab-Paclitaxel
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Alabama at Birmingham
Pancreatic Adenocarcinoma, Stage IIA Pancreatic Cancer
Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer
This phase II trial studies how well combination chemotherapy, gemcitabine hydrochloride, and radiation therapy before surgery works in treating patients with pancreatic cancer that has not spread to other places in the body and…
- Conditions
- Pancreatic Adenocarcinoma, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer
- Trial name
- NCT01897454
- Testing
- Fluorouracil, Gemcitabine Hydrochloride, Intensity-Modulated Radiation Therapy
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Albert Einstein College of Medicine
Pancreatic Ductal Adenocarcinoma
Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma
This is an open-label phase 1/2 study that will combine the chemotherapy agents gemcitabine and nab-paclitaxel with an oral hedgehog inhibitor LDE225 (Sonidegib).
- Trial name
- NCT01431794
- Testing
- LDE225-600mg, Gemcitabine, nab-paclitaxel
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pancreatic Cancer, Pancreatic Adenocarcinoma
Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates
The objective of this study is to estimate the R0 resection rate in patients with Resectable Pancreatic Ductal Adenocarcinoma (R-PDAC) as well as those with Resectable Pancreatic Ductal Adenocarcinoma (BR-PDAC) independently in…
- Conditions
- Pancreatic Cancer, Pancreatic Adenocarcinoma, Pancreas Ductal Adenocarcinoma
- Trial name
- NCT02723331
- Testing
- Nab paclitaxel, Gemcitabine
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- Academic Thoracic Oncology Medical Investigators Consortium
Borderline Resectable Pancreatic Ductal Adenocarcinoma
DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer
This clinical trial tests how well dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) with standard clinical evaluation works to assess treatment response for patients with pancreatic cancer that may be able to be…
- Trial name
- NCT07705919
- Testing
- Biospecimen Collection, Computed Tomography, Dynamic Contrast-Enhanced Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Pancreatic Cancer
Chemotherapy for Patients With Locally Advanced Pancreatic Cancer (LAPC) With Additional Chemo-radiotherapy (CRT) for Patients With Borderline Resectable Tumours
Treating patients with initial local non-resectable pancreatic cancer with a combination of oxaliplatin, irinotecan \& 5-FU(FOLFIRINOX), consolidated with chemoradiotherapy in potentially resectable patients, will result in a…
- Trial name
- NCT01397019
- Testing
- Oxaliplatin, irinotecan, 5-FU & leucovorin
- Where
- 3 sites in Denmark
- Volunteers
- 56 people
- Sponsor
- Per Pfeiffer
Pancreatic Cancer
Borderline Resectable Pancreatic Cancer Neoadjuvant Chemoradiotherapy Clinicaltrial-1
This study is to investigate whether neoadjuvant chemotherapy plus SBRT results in better outcomes compared with neoadjuvant chemotherapy alone and also compare the efficacy of gemcitabine plus nab-paclitaxel with SBRT and S-1…
- Trial name
- BRPCNCC-1 (NCT03777462)
- Testing
- Neoadjuvant gemcitabine plus nab-paclitaxel, Neoadjuvant gemcitabine plus nab-paclitaxel with SBRT, Neoadjuvant S-1 plus nab-paclitaxel with SBRT
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Changhai Hospital
Locally Advanced Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Carcinoma
Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC
The goal of this multicenter randomized controlled phase III trial is to compare two durations of neoadjuvant chemotherapy (NAT) with mFOLFIRINOX or gemcitabine-nab-paclitaxel (GnP) before attempt for surgical resection in…
- Conditions
- Locally Advanced Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Carcinoma, Pancreas Cancer, Neoadjuvant Chemotherapy
- Trial name
- ADVANTAGE (NCT06714604)
- Testing
- FOLFIRINOX or gemcitabine-nab-paclitaxel
- Where
- Sweden
- Volunteers
- 432 people
- Sponsor
- Sahlgrenska University Hospital
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas
Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance Pancreatic Cancer That May or May Not be Removed by Surgery
This phase I trial studies the side effects and best dose of radiosurgery boost following chemoradiation in treating patients with locally advanced pancreatic cancer that may or may not be removed by surgery.
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer
- Trial name
- NCT01739439
- Testing
- gemcitabine hydrochloride, hyperfractionated radiation therapy, intensity-modulated radiation therapy
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Fox Chase Cancer Center